AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04166214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging using intraoral cameras
Description: The SOPROCARE is intended for clinical practice of general dentistry, as an aid in the diagnosis of pit and fissure caries, as an aid to highlight dental plaque and gingival inflammations and as intra-oral camera to visualize anatomical details that are invisible to the naked eye or with a mirror. In CARIO mode, the camera helps the dental practitioner to highlight carious warning on pits and fissures of the occlusal side of the teeth. In DAYLIGHT mode, the camera enables you to visualize anatomical details invisible to the naked eye or with a mirror. In PERIO mode, the camera helps the dental practitioner to see the presence of dental plaque but also to highlight gingival inflammations . This mode offers to the dentist and/or hygienist a tool for an improved communication, motivation and education of his/her patients, who will then become aware of their oral health condition.
Study NCT00329108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprasidone hydrochloride
Description: Ziprasidone will be initiated at 80 mg/day on Day 1 and titrated to 120 mg/day from Day 3. From Day 7 the dosage may be adjusted on the basis of clinical status between 120 and 160 mg/day.
Study NCT00329108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: Olanzapine will be started at 15 mg/day on Day 1 until Day 7. The dosage will then be adjusted on the basis of clinical status between 15 and 20 mg/day.
Study NCT01094288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib ECT
Study NCT01094288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel IV infusion
Study NCT01389232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeriScaffold® Surgical Scaffold
Description: A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
Study NCT03255187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Description: Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in fish oil group are assigned to receive 2.5 g/day in divided doses. Each capsule contains 60% n-3 PUFA \[24% docosahexanoic acid (C22:6 n-3 DHA) and 36% eicosapentaenoic acid (C20:5 n-3 EPA)\].
Study NCT03255187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower seed oil supplementation
Description: Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in sunflower seed oil group receive 2.5 g/day in divided doses, and the capsules are identical as the fish oil capsules.
Study NCT00613795 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus GG
Description: Every 12 hours, the contents of a single capsule containing Lactobacillus GG will be suspended in 3 ml of water-soluble jelly. The suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second capsule will be suspended in 10 ml of sterile water and pushed through the NG tub followed by 10 mL of air to ensure complete administration.
Study NCT00613795 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Every 12 hours, the contents of a single identical placebo capsule containing the inert plant carbohydrate inulin will be suspended in 3 ml of water-soluble jelly. This suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second placebo capsule will be suspended in 10 ml of sterile water and pushed through eh NG tube followed by 10 mL of air to ensure complete administration
Study NCT04694092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive heart rate control with landiolol
Description: Intensive heart rate control preferably with the use of short-acting betablocker landiolol in combination with digoxin
Study NCT04694092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard approach to heart rate control
Description: Standard heart rate control with intravenous or oral beta-blockers and/or antiarrhythmic in combination with digoxin
Study NCT02316925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Setria glutathione supplement
Description: 500 mg/day capsule taken in the morning
Study NCT02247973 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: bone marrow derived mesenchymal stem cells from related donors.
Study NCT02316925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Crystalline Cellulose
Description: 500 mg/day capsule taken in the morning
Study NCT03134794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention applying the traffic light system (TLS)
Description: The TLS emerged to facilitate consumers' decisions. It has been applyied in medical decision making.
Study NCT04667832 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: selective coronary artery angiography
Description: Radial approach, invasive selective coronary angiography with selective contrast injection and filming in coronary arteries
Study NCT03789604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CS1001 monoclonal antibody
Description: Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle
Study NCT03789604 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CS1001 placebo
Description: Participant will receive CS1001 placebo 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle
Study NCT05012501 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: test NETs markers
Description: NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3), tissue factor, endotoxin, factor X, TAT complex, and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits.
Study NCT03369782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: rocuronium is administered in bolus and continuous infusion
Study NCT03369782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Sugammadex is administered just before reduction of the joint
Study NCT03369782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered as alternative to rocuronium in a bolus and in a syringe pump.~Placebo is administered as alternative to sugammadex
Study NCT01477567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009385
Study NCT01477567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00662337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride
Description: After a ten-hour fast and a one-hour fluid restriction prior to each dosing period, subjects received supervised dosing of their first 25 mg treatment with approximately eight ounces of water. Following a seven-day washout, the comparison treatment was administered according to thye same procedure.
Study NCT02687672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Transplantation of autologous stem cells
Study NCT00938938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Press Guide
Description: The press guide is a 1-page summary of the study findings, written by the investigators.
Study NCT03473990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity interval training
Description: 2 minute warm up, followed by 5x1min HIT intervals separated by 90 seconds active recovery (walking on the spot) and then a 2 minute recovery period. The high intensity bouts will be a pyramid of exercises (star jumps, mountain climbers and on-the-spot sprints)
Study NCT02644044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate
Description: 12.5 mg of methotrexate diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle.
Study NCT04483765 — intervention group
Intervention type: PROCEDURE
Intervention: spinal anesthesia
Description: patients undergoing transurethral resection of the prostate (TURP) and transurethral resection of the bladder (TURB) surgery under spinal anesthesia.
Study NCT02505386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Study NCT02505386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Study NCT01384877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 10mg/kg by subcutaneous infusion over 5.5 hours
Study NCT01384877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (D5W)
Description: Same volume as for lidocaine infusion, identical clear liquid in appearance, given in same device over same time period (5.5 hrs)
Study NCT01677286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg po bid x 12 months
Description: 100mg by mouth twice daily for 1 year.
Study NCT01258374 — intervention group
Intervention type: DRUG
Intervention: Raltegravir
Description: Raltegravir, 400 mg bid
Study NCT01258374 — intervention group
Intervention type: DRUG
Intervention: Darunavir
Description: Darunavir, 800 mg QD + ritonavir 100 mg QD
Study NCT00681200 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced health education
Description: health education and social support
Study NCT00681200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation program
Description: The TM program plus didactic-based health education classes
Study NCT01857752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT03000972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cement augmentation
Study NCT03000972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PFN-A Nail
Study NCT03000972 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PFN-A Nail
Study NCT02378272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care manager for depression
Description: District nurse (care manager for depression) providing clinical services ( in cooperation with GP) as patient information and education on patient's preferred treatment, development of care plan, assessment of patient's depressive symptoms and regular telephone contacts.
Study NCT01064011 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rt-PA thrombolysis
Description: patients will be administered a total of six doses of rt-PA (each 1 mg/ml) through the external ventricular drain every eight hours.
Study NCT01064011 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: endoscopic hematoma evacuation
Description: In the operating room under general anesthesia, the external ventricular drain will be removed and the burr hole enlarged to allow for entry of the endoscope. The neuroscope will be introduced through the burr hole down the prior external ventricular drain tract into the ipsilateral ventricle. utilizing a standard technique combining gentle aspiration, continuous irrigation, and grasping forceps,the intraventricular hematoma will be evacuated. After the evacuation the endoscope will be removed and an external ventricular drain will be reattached to a closed system and permitted to drain post-operatively.
Study NCT03243396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy
Description: Eight small-group sessions, including eight children and one guardian for each child, will meet separately, with joint activities in the final three sessions. TF-CBT will be delivered via community health volunteers in the community setting, and via selected teachers in the school setting--with two lay counselors leading the child group, and one leading the guardian group. Most TF-CBT components (psychoeducation, parenting, relaxation, cognitive coping, grief specific skills) will be delivered in groups, but 2-3 individual sessions mid-group will be used for imaginal exposure (i.e., talking about/processing traumatic events).
Study NCT02354326 — intervention group
Intervention type: RADIATION
Intervention: virtual non-calcium dual-energy computed tomography
Description: Undergo VNC DECT
Study NCT00423631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care and web
Description: A static web site containing cognitive and behavioral self management instructions.
Study NCT00423631 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care delivered by the primary care provider.
Study NCT01239485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Chemotherapy: irinotecan, etoposide, and cytarabine daily for 5 days (on days 0, 1, 2, 3, \& 4) -30 min: Atropin ivs 0 hour: irinotecan X mg/m2 in D5W 100 mL IV over 60 min 0 hour: etoposide 100 mg/m2 in x3 N/S mL IV over 60 min 12 hour: cytarabine 2,000 mg/m2 over 3 hr~\*if age ≤ 3 yrs: calculate all drugs in kg base (30kg=1m2) Irinotecan dose is escalated by 25-30% in successive cohorts. The starting irinotecan dose (level 1) is 20 mg/m2/dose on days 0 to 4.
Study NCT02354326 — intervention group
Intervention type: RADIATION
Intervention: computed tomography
Description: Undergo CT without VNC
Study NCT02786303 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Whole-body diffusion- weighted MRI
Study NCT04576000 — intervention group
Intervention type: DRUG
Intervention: Janus Kinase Inhibitor
Description: Janus Kinase inhibitor induction therapy will be administered according to Standard Of Care (SOC)
Study NCT03764124 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT imaging
Description: The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events were applied.
Study NCT01324297 — intervention group
Intervention type: OTHER
Intervention: skin test
Description: four patches of 2 x 3cm thin blotting paper will be soaked with an equivalent amount (0.1 mL) of aqueous methyl nicotinate in four different concentrations: 0.1, 0.01, 0.001, 0.0001 M. The four patches will then be applied at the same time to the inner forearm for 60 seconds.
Study NCT01923558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Donepezil Hydrochloride tablets,23 mg
Study NCT01923558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil Hydrochloride tablets,23 mg
Study NCT03711721 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food basket
Study NCT03711721 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-Use Therapeutic Food
Study NCT03151369 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Morphine
Description: patients with the visual analog scale over 3 will receive morphine
Study NCT00535470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.04% Mechlorethamine gel
Description: Mechlorethamine 0.04% PG applied to affected skin areas (lesions) once daily for up to seven (7) months. The frequency of application may be adjusted for toxicity. After seven (7) months, they will be terminated from the study.
Study NCT01649765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belimumab 10mg/kg
Description: belimumab 10mg/kg IV monthly
Study NCT01649765 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Normal Saline 250 ml
Study NCT01621074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: Ergogenic effect
Study NCT01621074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo effect
Study NCT02856958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve decompression
Study NCT02856958 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative
Description: Physical therapy
Study NCT03881683 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HRD and BRCA mutations
Description: Compare BRCA1/2 and HRD genes mutation detected from blood sample (20 ml) and biopsy
Study NCT04853485 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: All subjects with early psychosis will be divided into three subgroups determined by their psychotic symptoms and cognition. There are three rTMS strategies: (1) For subgroup 1, characterized by negative symptoms, iTBS over cerebellum and 1 Hz over right DLPFC; (2) For subgroup 2, characterized by cognition deficits, 20 Hz over the left inferior parietal cortex; (3) For subgroup 3, characterized by positive symptoms: 10 Hz over ACC. Ten to twenty sessions of rTMS will be delivered to each patients during the intervention period.
Study NCT04853485 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: All subjects with early psychosis will be divided into three subgroups determined by their psychotic symptoms and cognition. There are three rTMS strategies: (1) For subgroup 1, characterized by negative symptoms, iTBS over cerebellum and 1 Hz over right DLPFC; (2) For subgroup 2, characterized by cognition deficits, 20 Hz over the left inferior parietal cortex; (3) For subgroup 3, characterized by positive symptoms: 10 Hz over ACC. Ten to twenty sessions of rTMS will be delivered to each patients during the intervention period.
Study NCT04853485 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: All subjects with early psychosis will be divided into three subgroups determined by their psychotic symptoms and cognition. There are three rTMS strategies: (1) For subgroup 1, characterized by negative symptoms, iTBS over cerebellum and 1 Hz over right DLPFC; (2) For subgroup 2, characterized by cognition deficits, 20 Hz over the left inferior parietal cortex; (3) For subgroup 3, characterized by positive symptoms: 10 Hz over ACC. Ten to twenty sessions of rTMS will be delivered to each patients during the intervention period.
Study NCT01602107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor muscle strengthening exercises
Description: Participants will attend regular physical therapy visits (weekly X 2 weeks, bi-weekly X 4 weeks, and continuing monthly) until the time of their surgery. they will then see the physical therapist for assessment, exercise and advice at 2 and 4 weeks after their surgery. During physical therapy visits, patients will receive two sessions of biofeedback training, and at each visit will work on strength and motor control exercises for their pelvic floor muscles.
Study NCT01269515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: 90 mg QD
Study NCT03941951 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Non-impositive Program for Optimizing the Use of Antimicrobials
Description: Quasi-experimental intervention through the development of a Program for Optimizing the Use of Antimicrobials in the participating hospitals. The intervention will consist of the development of a consensus guide on the use of new antibiotics, its dissemination in Andalusian hospitals and an audit on the prescription of new antibiotics.
Study NCT00185965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG 7909
Description: 6 mg intratumoral injection, administered immediately before 2 Gy radiotherapy (RT) to a designated tumor lesion, about 24 hours later after a 2nd 2 Gy RT dose, then weekly for 8 additional weeks (total of 10 injections).
Study NCT01010191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar pill
Study NCT02093091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental caries was removed from primary molars and was filled with the recent filling material; Ketac Nano.
Description: Class I carious primary molars were selected. Dental caries was removed and cavities were prepared. The recent nano-filled RMGI filling (Ketac Nano) was used to fill these cavities.
Study NCT02093091 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dental caries was removed from primary molars and was filled with the conventional filling material;Vitremer
Description: Class I carious primary molars were selected. Dental caries was removed and cavities were prepared. The conventional RMGI filling (Vitremer) was used to fill these cavities.
Study NCT01719419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with placebo.